Articles by Topic "Drug discovery"

1. Why Do So Many Molecules Incorporate an “Oxadiazole Ring”? A Stability-Oriented Design Guide from Structural Effects to Application Storylines (with Product Navigation Tables 1–3)
   posted this at Mar 3, 2026

   1
   In drug discovery, chemical biology, and organic optoelectronic materials development, rework is often not caused by the “core function” failing. More commonly, it stems from insufficient stability and controllability of the results: along the same route and within the same structural ...
2. Why Do We So Often Add a “Morpholine Ring” to Molecules? — Definitions, Structural Features, and a Selection Guide to Morpholine/Thiomorpholine (with Tables 1–4)
   posted this at Mar 2, 2026

   2
   In drug discovery, agrochemical development, and industrial formulations, one of the most frequent reasons for rework is: the activity is there, but the compound is not sufficiently “usable.”
3. Quinoline vs Isoquinoline: How “Where the Nitrogen Sits” Changes Reactivity and Applications
   posted this at Feb 25, 2026

   1
   In drug discovery, catalysis, and materials chemistry, quinoline and isoquinoline are often treated as “pretty similar N-heteroaromatics.” But in real experiments, the differences most likely to trigger rework often come from one key factor: the position of the ring nitrogen.
4. The Role of 7-Membered Nitrogen Heterocycles in Drug Discovery: Microstate Management, Conformational Bias, and Developability Trade-offs (with Research Selection Navigator and Product Tables 1–3)
   posted this at Jan 19, 2026

   1
   7-membered N-heterocycles—as a structural module—are often used because.
5. Late-Stage Fluorination Toolbox: “Minimally Invasive Upgrades” for Lead Candidates： Four “Fluorine Knobs” → Two major routes (electrophilic vs nucleophilic) → An ¹⁸F-PET tracer branch → Selection navigation & representative product list
   posted this at Jan 18, 2026

   0
   In drug discovery, many molecules end up stuck in the same awkward spot: potency is good, but exposure is insufficient; selectivity looks fine, but metabolism is too fast; in vitro is beautiful, yet in vivo distribution is disappointing. In those moments, you usually don’t want to rebuild the ...
6. Targeted drug discovery: scarce and inefficient, what is the geometry of its effectiveness?
   posted this at Jun 9, 2025

   4
   Although target-based drug discovery is currently the dominant approach to drug discovery and development, the latest comprehensive assessment shows that its results are not as good as they could be. The number of drugs discovered by this approach is relatively small, and their therapeutic ...